Trintellix
| Chemical Name | vortioxetine |
| Dosage Form | Tablet (oral; 5 mg, 10 mg, 15 mg, 20 mg) |
| Drug Class | Unknown mechanism of action |
| System | Nervous |
| Company | Lundbeck |
| Approval Year | 2013 |
Indication
- For the treatment of major depressive disorder (MDD) in adults.
More on this drug: Clinical Trials
| Document Title | Year | Source |
| Trintellix (vortioxetine) Prescribing Information. | 2021 | Takeda Pharmaceuticals America, Deerfield, IL |
| Document Title | Year | Source |
| Pharmacoeconomic review report: vorioxetine hydrobromide (Trintellix). | 2020 | CADTH |
| Clinical review report: vorioxetine hydrobromide (Trintellix). | 2020 | CADTH |
| Assessment report: Brintellix. | 2020 | EMA |
| Document Title | Year | Source |
| VA/DoD clinical practice guideline for the management of major depressive disorder. | 2022 | Department of Veterans Affairs: Department of Defense |
| The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. | 2020 | Australian & New Zealand Journal of Psychiatry |
| Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. | 2017 | The Journal of Clinical Psychology |